首页> Basic & clinical pharmacology & toxicology> CYP3A4*22 may increase bleeding risk in ticagrelor users.

CYP3A4*22 may increase bleeding risk in ticagrelor users.

导出原文传递

翻译打印收藏纠错

第一作者： Hilkka,Liedes

第一单位： VTT Technical Research Centre of Finland Ltd., Oulu, Finland.

作者： Hilkka,Liedes ^[1] ; Juha,Pajula ^[2] ; Anna-Leena,Vuorinen ^[2] ; Francesco,De Pretis ^[3] ; Mark,van Gils ^[2] ; Kari,Harno ^[4] ; Mika,Lehto ^[5] ; Mikko,Niemi ^[6] ; Jaakko,Lähteenmäki ^[7]

作者单位： VTT Technical Research Centre of Finland Ltd., Oulu, Finland. ^[1] VTT Technical Research Centre of Finland Ltd., Tampere, Finland. ^[2] VTT Technical Research Centre of Finland Ltd., Kuopio, Finland. ^[3] Department of Health and Social Management, University of Eastern Finland, Kuopio, Finland. ^[4] Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.;Faculty of Medicine, Clinicum, University of Helsinki, Helsinki, Finland. ^[5] Department of Clinical Pharmacology and Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.;Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland. ^[6] VTT Technical Research Centre of Finland Ltd., Espoo, Finland. ^[7]

关键词 adverse drug events antiplatelet drugs ischemic heart disease pharmacogenetics polymorphism precision medicine

医学主题词人类(Humans);细胞色素P-450 CYP3A(Cytochrome P-450 CYP3A);出血(Hemorrhage);血小板聚集抑制剂(Platelet Aggregation Inhibitors);急性冠状动脉综合征(Acute Coronary Syndrome);治疗结果(Treatment Outcome)

DOI 10.1111/bcpt.13884

PMID 37162098

发布时间 2023-07-18

基金项目